Thrombolytic Science International
id:
thrombolytic-science-international-236-6183361
title:
Thrombolytic Science International
text:
Thrombolytic Science, LLC (TSI) is a private, clinical stage biopharmaceutical company that was founded in 2006 based on the research of Harvard scientist Victor Gurewich into the potential use of prourokinase to break up blood clots. Gurewich co-founded the company and the founding CEO is business person Alexis Wallace. TSI's lead drug candidate is a synergistic sequential dual therapy combination of mutant prourokinase and a small dose of tPA [Tissue Plasminogen Activator]. TSI is developing i
brand slug:
wiki
category slug:
encyclopedia
description:
original url:
https://en.wikipedia.org/wiki/Thrombolytic_Science_International
date created:
date modified:
2021-01-02T18:55:29Z
main entity:
{"identifier":"Q7798341","url":"https://www.wikidata.org/entity/Q7798341"}
image:
fields total:
13
integrity:
13